Trulicity 1.5 mg/.5mL (Dulaglutide) 1.5 mg/0.5 mL Injection, solution

Dulaglutide, the active ingredient in Trulicity 1.5 mg/0.5mL, is a glucagon-like peptide-1 (GLP-1) receptor agonist presented as a 1.5 mg/0.5mL injection, solution for subcutaneous use. It is used as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

GNH USA supplies Trulicity 1.5 mg/0.5mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Trulicity 1.5 mg/0.5mL is a glucagon-like peptide-1 (GLP-1) receptor agonist used to manage type 2 diabetes mellitus and associated cardiovascular risks.

- Type 2 Diabetes Mellitus: Improves glycemic control in adults and pediatric patients 10 years of age and older. - Cardiovascular Risk Reduction: Reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Trulicity 1.5 mg/0.5mL may cause various side effects, ranging from common to serious.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Abdominal pain - Decreased appetite - Dyspepsia - Fatigue

Serious or Rare Side Effects: - Thyroid C-cell Tumors: Risk of thyroid tumors, including medullary thyroid carcinoma (MTC). - Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. - Hypoglycemia: Increased risk when used with insulin secretagogues or insulin. - Hypersensitivity Reactions: Serious reactions, including anaphylactic reactions and angioedema. - Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe gastrointestinal reactions.

Trulicity 1.5 mg/0.5mL should be used with caution and certain precautions should be observed.

- Thyroid C-cell Tumors: Monitor for signs of thyroid tumors, including MTC. - Pancreatitis: Discontinue promptly if pancreatitis is suspected and do not restart if confirmed. - Hypoglycemia: Reduce the dose of insulin secretagogues or insulin if concomitant use is necessary. - Hypersensitivity Reactions: Discontinue and seek medical advice if serious reactions occur. - Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe gastrointestinal reactions. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Trulicity 1.5 mg/0.5mL may interact with other medications, potentially affecting their absorption or efficacy.

Major Interactions (Avoid): - Oral Medications: Delays gastric emptying, potentially reducing the absorption of concomitantly administered oral medications.

Moderate Interactions (Monitor Closely): - Insulin Secretagogues: Increased risk of hypoglycemia when used concomitantly. - Insulin: Monitor blood glucose levels closely to avoid hypoglycemia. - Medications with Narrow Therapeutic Index: Monitor drug levels adequately when concomitantly administered with Trulicity.